Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
764 A phase 1, first-in-human (FIH), open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.